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ABSTRACT 
	
Congenital Erythrocytosis (CE) are rare and heterogeneous clinical entities. They are 
caused by genetic deregulation of the erythroid production resulting in increased 
production of red blood cells (RBCs). Primary Congenital Familial Polycythemia 
(PCFP) is due to erythropoietin receptor (EPOR) mutations and is associated with 
reduced levels of serum erythropoietin (EPOs). Secondary CE are characterized by 
high EPOs levels, may be due to mutations of the oxygen-sensing pathway (OSP) 
genes: von Hippel-Lindau (VHL), hypoxia-inducible factor 2 alpha (HIF2A/EPAS1) 
and  prolyl hydroxylase 2 (EGLN1/PHD2).  
Within 106 patients followed in our centre with sporadic not myeloproliferative 
erythrocytosis we found 9 mutations (8,5%) in the involved genes. Here we report the  
functional studies of 1 novel PHD2 (c.1045G>A) and of 2 EPOR gene missense 
mutations (c.1013G>A and c.1022C>T). 
To evaluate the HIF transcriptional activity of PHD2 mutation, an in cellulo reporter 
assay has been performed, while the hydroxylation capacity of PHD2 variants has 
been tested with an in vitro Hydroxylation test. PHD2 variant does not show a clear 
loss-of-function of the PHD2 proteins. More sensitive tests could be developed and 
other PHD2 partners may be tested in this patient. 
The activation of EPOR mutated signaling was evaluated with a kinetic assay using 
transfected K562 cell lines. The EPOR signaling cascade results more active in 
mutated cells than in the WT cells when stimulated with EPO as shown by higher 
phosphorylation of STAT5 and ERK. Both mutations impair the C-terminal negative 
regulatory domain and determine gain-of-function in the EPOR signalling cascade. 
These are the first missense mutations of EPOR with a functional demonstrated 
activity that affect the EPOR signaling cascade. 
Other candidate genes need to be investigated to completely understand the ethiology 
of high hematocrit (HCT) level both in congenital and sporadic erythrocytosis 							
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RIASSUNTO 
 
Le Eritrocitosi Congenite (CE) sono entità cliniche rare ed eterogenee. Esse sono 
causate dalla deregolazione genetica della produzione eritroide con conseguente 
incremento della produzione delle cellule rosse del sangue (RBCs). La Policitemia 
Congenita Primaria Familiare (PCFP) è dovuta a mutazioni del recettore 
dell’eritropoietina (EPOR) ed è associata a bassi livelli di eritropoietina sierica 
(EPOs). Le CE secondarie, invece, sono caratterizzate da elevati valori di EPOs 
dovuti ad alterazioni dei geni dell’ Oxygen Sensing Pathway (OSP): von Hippel-
Lindau (VHL), hypoxia-inducible factor 2 alpha  (HIF2A/EPAS1) e prolyl 
hydroxylase 2 (EGLN1/PHD2).   
Nel nostro centro sono stati seguiti 106 pazienti con eritrocitosi sporadica non 
mieloproliferativa nei quali abbiamo trovato 9 mutazioni (8,5%) nei geni candidati. 
Al fine di valutare l’attività trascrizionale di HIF in presenza di PHD2 mutato è stato 
messo a punto un reporter assay in cellulo, mentre l’attività di idrossilazione di PHD2 
è stata testata con un hydroxylation test in vitro. Non è stata riscontrata una chiara 
loss-of-function per la variante di PHD2 nonostante il link mutazione-malattia. 
Pertanto si necessita lo sviluppo di test più sensibili oltre allo studio di altri geni 
partner.  
La cascata del segnale di EPOR mutato è stata studiata effettuando una cinetica di 
stimolazione su cellule K562 trasfettate. In seguito a stimolazione con EPO il 
signaling di EPOR è risultato più attivo in condizioni mutate rispetto al wild type 
rilevando alti livelli di fosforilazione di STAT5 e ERK. Entrambe le mutazioni 
compromettono il dominio regolatore negativo C-terminale di EPOR causando una 
gain-of-function del recettore. 
Queste sono le prime mutazioni missenso in cui in cui è stata rilevata 
un’iperattivazione dei componenti della cascata del segnale di EPOR. 
Altri geni candidati devono essere investigati per comprendere completamente 
l’eziologia degli alti valori di ematocrito (HTC) sia nei casi di eritrocisi sporadiche sia 
in quelle congenite. 
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INTRODUCTION 
 
Erythrocytes (RBCs), are the main cellular component of blood: they constitute 
approximately one-half of blood volume. Their primary function is to transport 
oxygen to body tissues. Oxygen, in turn, is the terminal electron acceptor of the 
mitochondrial electron transport chain, which allows for the generation of high levels 
of ATP from glucose. The primary protein component of RBCs is the iron-containing 
hemoglobin (HB) molecule, which is the chief carrier of oxygen to the tissues. HB 
has a quaternary structure assembled by two α- and two β-peptide chains that are 
arranged into a tetramer form identical halves, each of which is composed of one α 
and one β chain. Using the heme iron moiety, oxygen is loaded in the respiratory 
organs and off-loaded in the other tissues of the body. During this process, the HB 
molecule changes its conformational state moving from a tense state to a relaxed 
state. The affinity of HB toward oxygen is reduced to allow oxygen to be released at 
sites of low oxygen tension. The affinity of HB for oxygen can be influenced by pH, 
pCO2, temperature and by 2,3-bisphosphoglycerate (2,3-BPG), which binds directly 
to the HB molecule better than O2. Indeed, it diminishes with the decrease of pH or 
increases in either pCO2 or 2,3-BPG, which is synthesized by the enzyme 2,3-BPG 
mutase (BPGM).  
Low concentrations of RBCs cause inefficient delivery of oxygen to the tissues, 
leading to the inability to meet metabolic demands. At the same time, high 
concentrations of RBCs can cause hyperviscosity, and thus a predisposition to 
thrombotic events such as cerebrovascular accidents. This need for precise regulation 
is all the more critical given that the RBCs have a finite lifetime of approximately 120 
days, mandating the production of 2x109 such cells per day. 
The close relationship between oxygen delivery and RBCs needs the ability of red 
cells mass (RCM) to change in response to fluctuations in oxygen tension (Figure 1). 
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Fig. 1: The balance of RCM is regulated by the erythropoietin hormone which synthesis is under 
control of the OSP consequently to tissue normoxia or hypoxia conditions. 
 
The glyco-protein hormone erythropoietin (EPO) regulates RCM responding to 
oxygen tension changes (1–3).  
In adults, the main source of EPO is the kidney and the committed cells (Renal Epo 
Producing Cells, REPC) are the peritubular interstitial (4-10) found in the renal cortex 
(predominantly juxtamedullary region). (Figure 2). 
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Fig. 2: Districts with EPO-producing capacity. Hepatocytes in liver and mostly the REPC in kidney are 
the major contributor of EPO synthesis. 
 
Glyal cells in the central nervous system have recently been identified as another 
source of EPO (11).  
EPOs levels in normal subjects are about 10 pg ml−1. Under tissue hypoxia 
conditions, the EPO gene transcription is triggered, with a consequent increase in 
EPO circulating levels.  
EPO binds to the EPOR, which is expressed on erythroid progenitors, and initiates an 
intracellular signaling cascade resulting in the recruitment and activation of Janus 
kinase 2 (JAK2), which, in turn, activates the STAT5 (signal transducer and activator 
of transcription 5) transcription factor and two other intracellular signaling pathways, 
the MAPK (mitogen-activated protein kinase)-ERK pathway and the PI3K 
(phosphoinositide 3-kinase)-AKT pathway. Collectively, these signals lead to the 
inhibition of apoptosis and the expansion and differentiation of erythroid precursors 
(12).  (Figure 3). 
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Fig. 3: EPO binds to a EPOR homo-dimer leading to activation of the EPO-EPOR signaling cascade. 
Main signaling pathways activated by EPO are JAK2/STAT5 pathway, PI3K pathway, RAS/MAPK 
pathway.  
 
The result is an increase RCM that serves to improve oxygen delivery, and down-
regulates EPO levels in a negative feedback loop to maintain RCM at an appropriate 
level for a given tissue oxygenation. 
 
Erythrocytosis occurs when there is an increase in the RCM to more than 125% of the 
predicted value for the body mass of the patient (13). This condition usually becomes 
manifest with HB levels above 185 or 165 g/L (14) HCT above 51 or 48% (15), 
respectively in males and in females. 
The HB concentration and the HCT can be influenced by the plasma volume (16). 
Any reduction in plasma volume may cause a relative erythrocytosis with raised HCT 
and HB levels. In contrast, true erythrocytosis has many causes (Table 1). 
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Relative 
Dehydration  
Stress 
Diuretics 
Burns 
Neonatal 
Absolute 
Primary 
Polycythemia Vera (PV) 
Primary Familial and Congenital Polycythemia (PFCP) 
Secondary 
Appropriate secretion of EPO 
Altitude 
BPCO 
Cardiovascular shunt 
Pickwick Syndrome 
High affinity HB 
Deficiency of BPGM  
Methemoglobinemia 
Smoke 
Inappropriate secretion of EPO 
Renal Mass (cysts, hydronephrosis, cancer, transplant) 
Oxygen Sensing Pathway (OSP) polycythemias 
Neoplasms 
Tab. 1: Classification clinical / pathological erythrocytosis  (congenital forms are in italics) 
 
Primary erythrocytosis is associated with low or subnormal EPOs levels and is 
characterized by the hyperactivity of erythroid progenitor cells without requirement 
for EPO. These findings are consistent with an intrinsic defect of erythroid 
progenitors and related to aberrant JAK2-mediated signaling. In the case of secondary 
erythrocytosis, the EPOs level is inappropriately high for the RCM. 
The most common example of primary erythrocytosis is Polycythemia Vera (PV), 
which is an acquired stem cell disorder that exhibits trilineage proliferation. Most 
clinical symptoms in PV are related to clonal erythropoiesis, but the disorder also 
affects the megakaryocytic and myeloid lineages. PV is uniformly associated with 
acquired gain-of-function mutations in the JAK2 gene (OMIM #147796). Almost all 
cases (95%) of PV present a point mutation located in exon 14 of  JAK2 that produces 
a V617F substitution (17–21); a small percentage (3%) of cases are associated with a 
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mutation involving exon 12 of JAK2. With both types of mutations, the resulting 
constitutive activation of the kinase bypasses the need for the activation of EPOR by 
EPO (17) and leads to the EPO-independent proliferation of erythroid precursors. The 
marked expansion of RCM leads to downregulation of EPO synthesis and hence low 
EPOs levels. 
A less frequent form of primary erythrocytosis arises from mutations in the EPOR 
gene (OMIM #133171) (22). It is associated with subnormal or undetectable EPOs 
levels. All mutations cluster within a 180-bp region in exon 8. Most of them result in 
C-terminal truncations that remove a cytoplasmic domain containing binding sites for 
negatively regulatory factors. The mutated receptor is hypersensitive and, when 
stimulated by EPO, produces abnormally prolonged activation of downstream 
signaling pathways. 
The causes of secondary erythrocytosis are heterogeneous and include chronic lung 
disease, right-to-left cardiopulmonary shunts, sleep apnea, high-altitude living, and 
less commonly, EPO-producing tumors that can be either benign or malignant. 
Various tumors may secrete EPO, but it occurs more commonly in renal cell 
carcinoma, cerebellar hemangioblastomas, and hepatocellular carcinoma. Upon 
removal of the tumor, the EPOs level drops, and HCT returns to normal levels (23). 
Secondary erythrocytoses can also be caused by molecular lesions which ultimately 
lead to impaired oxygen delivery. Causes in this category include high–oxygen 
affinity HB variants (HBB, OMIM #141900; HBA1, OMIM #141800; HBA2, OMIM 
#141850), deficiency of BPGM (OMIM #613896), or methemoglobinemia. A major 
cause of erythrocytosis related to abnormal HB function is the presence of a high–
oxygen affinity HB variant. Approximately 100 HB variants have been described, and 
all exhibit a reduced ability to release oxygen to the tissues. Mutations that cause 
high–oxygen affinity variants result in structural alterations that occur at the α1β2 
interface and in regions involved in stabilizing the tense state of HB (24). The 
resultant oxygen dissociation curve is shifted to the left, thereby depressing the p50 
value, which is a measure of oxygen affinity. Most high–oxygen affinity HB variants 
are undetectable by routine laboratory tests and must be diagnosed by determining the 
oxygen-dissociation curve, an assay that is usually performed in specialized centers 
(24). They are often misdiagnosed. Screening of a group of idiopathic erythrocytosis  
(IE) patients recently detected these HB variants at a prevalence of 3% (25). High–
oxygen affinity HB variants exhibit autosomal dominant transmission and are often 
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associated with a family history. Sequencing both the α- and β-globin genes is also 
helpful in diagnosing this form of erythrocytosis (25). 
Deficiency of BPGM results in decreased 2,3-BPG levels, which causes the HB 
molecule to remain in a high-affinity state. Mutations that impair BPGM function are 
characterized by erythrocytosis but are very rare. They are inherited in an autosomal 
recessive pattern and are associated with seemingly normal EPO levels that are 
inappropriately high for the RCM (26). Methemoglobinemia is another cause of 
deregulated oxygen delivery from HB (27). During normal oxygen delivery, there is 
spontaneous oxidation of the ferrous iron contained in the heme moiety to the ferric 
state. Consequently, HB is converted to the methemoglobin form. This form is less 
efficient at binding oxygen, and in some individuals there is methemoglobinemia with 
a compensatory erythrocytosis. Methemoglobinemia can develop from three causes: a 
HB M variant; or deficiency of cytochrome b5 reductase, which converts the ferric 
ion to a ferrous ion, and, extremely rarely, cytochrome b5 deficiency (27). The HB M 
group of variants has structural alterations of the heme pocket due to amino acid 
changes that allow spontaneous oxidation of the ferrous ion. These variants are 
inherited in an autosomal dominant manner. The α-globin chain variants present at 
birth, whereas the β variants manifest postnatally as chain synthesis switches from γ- 
to β-globin. HB Ms are easily distinguished by routine laboratory tests, in contrast to 
high–oxygen affinity HB variants. 
To conclude, acquired erythrocytosis usually manifest at mature ages and can be 
subdivided into two groups on the basis of clonality: PV is clonal, and other acquired 
secondary forms caused by tissue hypoxia or EPO-producing tumors are polyclonal. 
In most instances erythropoiesis is polyclonal and, in familial cases it is inherited in a 
Mendelian manner.  
Thus, absolute erythrocytosis can arise from:  
• Intrinsic defects in erythroid progenitors that lead to hypersensitivity to EPO 
(PV and EPOR defects).  
• Molecular defects that impair the ability of HB to deliver oxygen to tissues 
and that result in tissue hypoxia and hence activation of the EPO pathway 
(Pathological HB, methemoglobinemia) 
• Defects in the OSP resident in the kidney and liver that transduces changes in 
oxygen delivery to changes in EPO gene transcription (OSP polycythemias);  
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• Physiologic or pathophysiologic changes aside from HB defects that also lead 
to inappropriately high levels of EPO and excessive activation of the EPO 
pathway (a category that also includes EPO-producing tumors)(secondary 
erythrocytosis); 
 
Congenital and familial erythrocytosis can be either primary or secondary and are 
associated with an array of EPOs levels, which is indicative of the multiple origins of 
this disorder. One of the familial erythrocytosis is due to EPOR mutations, which is 
inherited in an autosomal dominant manner (Table 2) (28). It is designated Familial 
Erythrocytosis Type 1 (ECYT1, number 133100) in the Online Mendelian Inheritance 
in Man (OMIM) (http://www.ncbi.nlm.nih.gov/sites/entrez? db=omim). The other 
three recognized forms of familial erythrocytosis, ECYT2-4, are secondary 
erythrocytoses that derive from a deregulated EPO production due to mutations in the 
OSP.  
CE are the focus of the remainder of this thesis.  
 
Name OMIM Gene Inheritance EPO Clinical 
Feature(s) 
ECYT1 133100 EPOR Autosomal 
dominant 
Low - 
ECYT2 263400 VHL Autosomal 
recessive 
High Stroke, 
hemangiomas, 
pulmonary 
hypertension 
ECYT3 609820 PHD2 Autosomal 
dominant 
Normal Paraganglioma 
ECYT4 611783 HIF2α Autosomal 
dominant 
High Pulmonary 
hypertension, 
thromboses 
Tab. 2: NCBI classification of CE (HB and BPGM forms not shown). 
 
CE may be characterized by high levels of EPOs or inappropriately high. These 
Secondary Erythrocytosis result from mutations in genes that encode proteins 
embroiled in OSP. It has been documented gene mutations in hypoxia inducible factor 
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2alpha (HIF2α), the prolyl-hydroxylase 2 (PHD2) and the tumor-suppressor Von 
Hipple-Lindau (VHL) (29). 
EPO production grows in conditions of hypoxia or anemia due to reduced oxygen 
tension. In fact, under normoxia, hydroxylation of HIF2α subunits by prolyl-
hydroxylases is required for binding to the pVHL–E3-ubiquitin ligase complex. After 
polyubiquitination, HIF2α is degraded by the proteasome. During hypoxia, 
HIF2α subunit is not degraded and translocates to the nucleus where it binds to the 
HIF-β subunit. HIF-α/β heterodimers then bind to HIF-DNA consensus-binding sites 
resulting in increased transcription of more the 200 HIF-target genes (Figure 4), for 
example, EPO, VEGF, and glucose transporter-1. HIF2α is the main isoform of HIF 
and it’s involved in the regulation of EPO transcription. Furthermore it also regulates 
other genes involved in cell survival under conditions of low oxygen tension as the 
gene of heme-synthase (ALAS2), the production of globin chains (GATA1) and iron 
regulation (TRF2, TF) (30-34). 
 
Fig. 4: Representation of the proteins involved in the OSP and their functional mechanism in base on 
tissue oxygenation conditions. 
 
The VHL gene (OMIM #608537) maps on the short arm of the third chromosome 
(locus 3p25.3) and spans 10 kb. The VHL gene encodes a 4.7 kb mRNA translated 
from two translational initiation sites (+1 and +54). These 2 protein products are a 
30-kD full-length form (p30) formed by 213 amino acids and a 19-kD smaller 
form (p19) formed by 160 residues, both are functionally active (35). pVHL is a 
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component of the protein complex that includes elongin B, elongin C, and cullin-2, 
and possesses ubiquitin ligase E3 activity (Figure 5). 
     
 
Fig. 5: Structural representation of the protein encoded by VHL gene. 
 
More than 400 germline mutations in the VHL gene have been described as associated 
with the VHL disease (OMIM #193300) (36).  
VHL syndrome is a dominantly inherited familial cancer syndrome predisposing to a 
variety of malignant and benign tumors but VHL disease is outside the scope of this 
thesis. 
The first loss-of-function mutation in the VHL gene associated with CE was first 
described in more than 100 individuals from about 80 families living in the mid-
Volga River region of European Russia named Chuvashia. There erythrocytosis is 
endemic, whereas its worldwide frequency is very low. Chuvash polycythemia 
derives from a homozygous variant c.598C>T (p.Arg200Trp) in VHL gene (37). Also 
in Italy on the island of Ischia outside the bay Naples, and in non-Chuvash had been 
observed the VHL c.598C>T homozygosity mutation. Both non-Chuvash and Italian 
patients had the same haplotype as the Chuvash cohort, suggesting a common 
ancestor, which suggested this mutation may be endemic in other parts of the world 
(38, 39). Sixteen additional VHL variants associated with CE have also been 
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described. Four of them presented in the homozygous state, whereas the other cases 
were either compound heterozygosity or heterozygotes. VHL is associated with 
erythrocytosis (CE type 2; MIM #263400; Table 2) it is considered a recessive 
disease. 
 
PHD2 is an enzyme encoded by the EGLN1 gene (OMIM #606425), which is located 
on chromosome 1q42.1, and it is comprised of five exons (Figure 6). There are three 
PHD isoformes (PHD1, PHD2, and PHD3), but PHD2 is the primary functional 
isoform that catalyzes the prolyl hydroxylation of HIF-α, using oxygen as a 
cosubstrate (40, 41).  
 
 
Fig. 6: PHD2 domains and its tridimensional structure 
 
CE type 3 (OMIM #609820) is characterized by loss-of-function mutations of PHD2 
(Table 2) with autosomal-dominant inheritance.  
The c.950C>G, p.Pro317Arg was the first mutation described (41) in three members 
of two generations of a family. This mutation resulted in a substitution in a highly 
conserved region of the protein. In vitro functional expression studies show that the 
mutant protein had significantly decreased enzyme activity. In the son and daughter of 
the propositus, the HCT was elevated despite inappropriately normal EPOs levels, 
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suggesting deregulated EPO production.  
Since then, more than 22 patients were found to carry 16 mutations in PHD2 gene, all 
of them heterozygous, and the mutations include: 12 missense, two nonsense, one 
small duplication, and one small deletion. Among missense mutations, the c.471G>C 
(p.Gln157His) was found to coexist with the JAK2 p.Val617Phe somatic mutation, 
the latter probably being the primary cause of the disorder. Meanwhile, the c.471G>C  
mutation has been categorized as a SNP (rs61750991) with a frequency of around 2% 
in the normal population although some studies refer to a higher frequency (42, 43). 
Interestingly, one particular mutation (p.His374Arg) has been described in a patient 
with an erythrocytosis associated with a recurrent paraganglioma (44).  
 
The HIF2α gene (MIM #603349), is located on chromosome 2p21, it has 16 exons 
and spans at least 120 kb.  
At least three transcript variants encoding three different isoforms have been found 
for this gene, HIF1α, HIF2α, and HIF3α. HIF1α was first identified as a mediator of 
EPO induction in response to hypoxia in vitro (45), however HIF2α was later 
confirmed to have the major role to induce EPO expression (46-49). The degradation 
of HIF2α occurs via the hydroxylation of the Proline residues in position 405 and 531 
becoming then a target for the VHL complex. 
 
 
Fig. 7: Domains and several crucial residues of HIF2α 
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Mutations in exon 12 of HIF2α are responsible of familial erythrocytosis type 4 
(OMIM #611783) with autosomal-dominant inheritance. At present, in 22 patients 
(eight sporadic cases and four families) heterozygous HIF2α  mutations have been 
reported. p.Gly537Trp, p.Gly537Arg, p.Met535Val, and p.Pro534Leu (49-51) are the 
first missense HIF2α mutations found in erythrocytosis patients. The group of Martini 
in 2008 (52) described another pathogenic mutation, p.Met535Ile, and more recently, 
three additional missense mutations have been described, p.Asp539Glu, p.Met535Thr, 
p.Phe540Leu (53, 54). Whereas in 2012 the group of Lorenzo (55) identified a 
germline heterozygous missense mutation c.1121T>A (p.Phe374Tyr) in exon 9 in a 
polycythemic patient who developed pheochromocytoma/paraganglioma.  
Overall, more than 160 known mutations are associated with CE and the majority of 
them (about 100) are in globines. However, more than 70% of cases of erythrocytosis 
the molecular cause is not recognized. Therefore, we refer to these cases as IE. 
Among CE, PFCP is characterized by reduced or inappropriately low level of EPOs 
due to EPOR germline mutations causing a gain-of-function of the receptor. (56, 57).  
The coding region of the EPOR gene is contained within 8 exons spanning 
approximately 6 kb. Its cytogenetic location is 19p13.2, which is the short arm of 
chromosome 19 at position 13.2. The primary transcript 2,056 bp long encodes the 
EPOR which is a member of the cytokine receptor family, a protein of 508 amino 
acids (MW 66 kDa) (figure 8). 
Alternatively spliced forms of the EPOR have been identified, one of which has a 
truncated cytoplasmic domain. The shortened transcript is expressed at high levels in 
immature erythroid progenitor cells. In contrast, the expression of the full-length 
receptor increases as progenitor cells mature (58). 
De la Chapelle et al. in 1993 (28) discovered the first mutation in the EPOR gene in a 
successful Finnish sportsman and others 29 family members. Subsequently, more than 
26 heterozygous variants have been found in patients with CE. All of these mutations 
are located in exon 8, which encodes the C-terminal negative regulatory domain of 
the protein. In total, 19 are frameshift or nonsense mutations leading to cytoplasmic 
truncation of the receptor and loss of the C-terminal negative regulatory domain 
(Figure 8). All these 19 mutations induce a gain-of-function of the receptor and are 
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associated with PFCP. Of the remaining variants, six are missense mutations 
(c.1138C>G, c.1310G>A, c.1462C>T, c.1460A>G, c.1362C>G, c.1445G>A) (59, 60). 
  
 
Fig. 8: 3D representation of EPOR with all cytoplasmic residues responsible for the receptor  
activation or inhibition. 
 
In spite of its cause, high numbers of RBCs and high levels of HCT resulting in 
hyperviscosity may cause signs and symptoms ranging from headaches, dizziness, to 
epistaxis, dyspnea on exertion. Thrombotic and hemorrhagic events with an increased 
morbidity and mortality have also been described. Clinical symptoms can be 
effectively reduced by bloodletting, but the recovery of normal HCT is not necessarily 
reduce cardiovascular complications (61). 
Among CE, the cohort of Chuvash patients is today the most widely studied. The 
homozygotes cases had a lower survival compared to heterozygous subjects  mainly 
due to a high incidence of both arterial and venous thrombosis (62),  
There is little information regarding the clinic of patients with PHD2 mutations. 
Thromboembolic events have been reported (63, 64) even at a young age and overall 
it seems that the clinical risk of these patients is similar to those with Chuvash 
erythrocytosis (65). 
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Paragangliomas seem to be associated with mutations of HIF2α (66).  
Yet little is known about the clinical of erythrocytosis due to alterations of EPOR.  
In conclusion, high HCT and increased viscosity can cause various complications, 
including thromboembolic events also in young age, but in the absence of clinical and 
biomolecular data currently not available, it is not possible to draw a clear picture of 
these patients and even less, to determine what is their best management. 
In the present study, we report our experience on a large cohort of sporadic adult 
patients with high HCT, not affected by PV or acquired secondary erythrocytosis and 
we describe the functional activity of 1 PHD2 and 2 EPOR genes novel mutations. 																																					
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MATERIALS AND METHODS 
 
PATIENTS 
Among patients referred to our surgery with high HB and/or HCT levels (male: HB > 
185 g/L, HCT > 52%, females: HB > 165 g/L and HCT > 49%) we selected sporadic 
adult cases in whom an absolute erythrocytosis has been diagnosed, but PV and 
secondary acquired erythrocytosis were excluded. Therefore, we collected a careful 
medical history paying particular attention to the familial history with the main aim to 
identify other cases of Erythrocytosis in the kindred. We also registered the patients’ 
clinical symptoms giving particular attention to: headache, dizziness, paresthesia, 
aquagenic pruritus, previous haemorrhages or thrombosis. A careful clinical 
examination was carried out mainly for reveal hepatosplenomegaly, angiomas, 
hemangiomas and altered cardiovascular function. 
In all patients, arterial blood gas analysis, abdominal ultrasonography to evaluate 
liver, spleen and kidneys, had been performed. Echocardiography and Doppler 
ultrasound had been performed if appropriate.  
When secondary erythrocytosis (cardiac, pulmonary, renal) had been ruled out, we 
evaluated EPOs (EIA method) and we searched JAK2 mutations (both V617F and 
exon12 mutations) to exclude PV. P50 evaluation was carried out with Rapid Point 
405 Analyzer (Siemens) to identify high oxygen hemoglobinopathies. When found 
P50 high values, the germline and somatic DNA samples had been sent to specialized 
centers for the study of hereditary hemoglobinopathy. Thereafter, if erythrocytosis is 
considered secondary/reactive we excluded the patients from the study. 
 
RBC-Granulocytes isolation was performed on patients’ venous peripheral blood 
samples (each 5-10 ml total) collected in four 3mL EDTA tubes each. Complete 
blood counts were carried out with Sysmex XP300 cell counter to ensure the samples 
had cell counts within the reference range.  
We executed a Histopaque-1077 (Sigma Aldrich, St. Louis, MO USA) density 
gradient separation (Figure 9) following the protocol below: 
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1. Pipet 5ml Histopaque-1077 in 15ml conical centrifuge tube 
2. Carefully layer 5ml EDTA blood atop the Histopaque-1077 layer 
3. Centrifuge at 400 x g for 30 min at room temperature 
4. Aspirate RBC - Granulocytes (bottom layer) and transfer to 1,5ml Eppendorf 
tube  
 
Fig. 9: Blood separation in Histopaque-1077 density gradient. 
 
The genomic DNA was then extracted with automatic extractor Maxwell 16 System 
(Promega) (Figure 10) that uses a paramagnetic-particle handling system that 
processes samples using Maxwell reagent kits, providing consistent yield and purity. 
The kit is optimized to process a wide range of volumes of fresh or stored human 
blood samples. Up to 400µL of blood sample can be processed to yield up to 15µg of 
DNA. 
 
 
Fig. 10: Maxwell 16 System automatic extractor (Promega). 
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The presence of JAK2 V617F mutation was examined with Polymerase Chain 
Reaction (PCR) analysis and allele-specific quantitative PCR (qPCR) for the 
definition of the allelic burden if present. JAK2 exon 12 mutations were searched by 
Sanger sequencing. 
The germline DNA was collected by brushing the oral mucosa using Charge Switch 
gDNA Buccal Cell Kit (Invitrogen) to check the presence of mutation in other cell 
lines if found. 
In cases of low EPOs values we proceed in the first instance to search for mutations in 
EPOR, whereas when EPOs was elevated or inappropriately high we proceed to 
analyze VHL, PHD2 and HIF2α genes. (Figure 11). 
 
 
Fig. 11: Flowchart genetic investigations EI. 	
For selected patients we drew a genetic profile regarding the molecular investigation 
of EPOR, PHD2, VHL or HIF2α genes.  
The amplified genomic areas in exam were obtained by PCR analysis. We designed 
all primers using Primer 3 software (http://frodo.wi.mit.edu/primer3) (Table 3). 
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PRIMERS EXON ANNEALING CYCLES 
EPOR F 5’ – gcctctatgactgggagtgg – 3’ 
EPOR R 5’ – ctgagagaggcctcgccat – 3’ 8 60°C for 1’30” 40 
HIF2A F 5’ – tgacacagccaagtctgagg – 3’ 
HIF2A R 5’ – gtatcagatggctggggaga – 3’ 12 60°C for 1’30” 40 
VHL 1F 5’ – agcgcgttccatcctcta – 3’    
VHL 1R 5’ – gcttcagaccgtgctatcgt – 3’ 1 60°C for 50” 40 
VHL 2F 5’ – ctcccaaagtgctgggatta – 3’ 
VHL 2R 5’ – tggataacgtgcctgacatc – 3’ 2 60°C for 50” 40 
VHL 3F 5’ – gcaaagcctcttgttcgttc – 3’ 
VHL 3R 5’ – caaaaatgccaccaccttct – 3’ 3 60°C for 50” 40 
PHD2 1AF 5’ – gcacaggccctattctctca – 3’ 
PHD2 1AR 5’ – ggcctttacttttcccttgg – 3’ 1 60°C for 40” 35 
PHD2 1BF 5’ – ggccaagggaaaagtaaagg –3’ 
PHD2 1BR 5’ –gaagtcgtccaccacacag– 3’ 1 60°C for 40” 35 
PHD2 1CF 5’ – tctgtgtggtggacgacttc – 3’ 
PHD2 1CR 5’ – ccttacggggagctacacaa – 3’ 1 60°C for 40” 35 
PHD2 2F 5’ – tcttgtgttccctataaatgttaatgt -3’ 
PHD2 2R 5’ – tccactcctaatacctgagactga –3’ 2 60°C for 40” 35 
PHD2 3F 5’ – ttgtccttgcatcagtgccat – 3’ 
PHD2 3R 5’ – cagattccctcctgtcctacc – 3’ 3 60°C for 40” 35 
Tab. 3: Primers sequences for PCR analysis. In the table are also reported annealing temperatures and 
cycles of all PCR we tuned.  
 
The amplification by PCR was performed, in a volume of 12.5 µl, according to 
the protocol given in table 4, using GoTaq® Colorless Master Mix (Promega) 
All annealing temperatures and reaction cycles are described in table 3. 
 Quantity µl 
GoTaq® Colorless Master Mix 6,25 
Primers Forward (100ng/µl) 10µM (0,3 µM final) 1 
Primers Reverse (100ng/µl) 10µM (0,3 µM final) 1 
H20 Pyrograd 2,75 
DNA 1,5 
Tab. 4: PCR reaction mix. 
	 29	
We evaluated the success of the reaction with electrophoresis on 1,5% agarose gel 
TBE 1X colored with GelRed (Biotium), loading 5 µl of amplification product. 
The amplification product had been then purified with ExoSAP-IT (Affymetrix) in 
order to remove primer excess, the single-stranded DNA fragments and the free 
dNTPs in solution.  
To 1µl of PCR product it was added 1µl of enzyme; then mixture was incubated in a 
thermocycler (37° C for 15 minutes, then at 80° C for 15 minutes for enzyme 
inactivation). 
After the purification we performed the sequencing reaction using an automatic 
sequencer ABI-PRISM 3100 Genetic Analyzer (Applied Biosystem). 
The sequencing reaction was performed from 100-500 ng of nucleic acid according to 
the protocol given in the BigDye Terminator v1.1 kit (Applied Biosystems) (Table 5). 
The thermal profile of the reaction is described in table 6 . 
 
Reaction mix Vol (µl) 
Purified DNA  100-500 ng 
primer Forward/Reverse 
(10 µM) 1 
BigDye 1.1 2 
H2O Pyrograd 3  
Tab. 5: Sequencing reaction mix. 
 
T (°C) Time cycles 
96 10'' 
 
30 
60 5'' 
60 4' 
Tab. 6: Sequencing reaction thermal profile. 
 
Then we purified the obtained amplification products with GE Healthcare columns 
(Buckinghamshire); 4 µL of amplification product were mixed with 16 µL of 
formamide and loaded into the automated sequencer. 
The electropherograms were analyzed with the software Chromas (Winlmp Self-
Extractor Copyright 2000 Technelysium Pty Ltd) and sample sequences alignment 
with the wild type genes sequences was performed using BLAST software (http: 
//www.ncbi. nih.gov/BLAST). 
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FUNCTIONAL STUDY OF PHD2 MUTATION To	evaluate	 the	PHD2	mutation	 function,	 in	 cooperation	with	 the	 group	 led	by	Prof.	 Sylvie	 Hermouet	 University	 of	 Nantes,	 France)	 we	 proceeded	 with	 the	following	4	steps:	1. Computational	study;	2. Construction	of	mutant	plasmids;	3. In	cellulo	luciferase	reporter	assay	based	on	hypoxia	response	elements	(HRE)	reporter	gene	to	test	the	HIF	transcriptional	activity;	
4. In	vitro	hydroxylation	test	 to	assess	 the	hydroxylation	capacity	of	PHD2	variants;	 	 
IN SILICO STUDY 
Conservation of sequences and residues can provide information on functional 
significance. 
The mutation identified by nucleotide sequencing had been submitted to a	preventive	computational	 study	 in	 prediction	 sites	 using	 three	 software:	 POLYPHEN-2	 of	Harvard	(67),	SIFT	of	the	Craing	J.	Venter	Institute	(68),	and	MUTATION	TASTER	by	 Team	 Charitè	 (69).	 The	 resulting	 data	 defined	 whether	 the	 nucleotide	variation	alters	or	not	the	protein.		We	 studied	 also	 the	 conservation	 of	 the	 mutated	 residue	 in	 different	 animal	kingdoms	 to	 provide	 information	 on	 its	 functional	 significance.	 To	 assess	 the	conservation	 of	 the	 mutated	 residue	 we	 generated	 a	 multiple	 sequence	alignment	covering	a	huge	range	of	taxa	from	different	phyla.	Using	the	MULTIZ	whole	genome	multiple	alignment	algorithm	(70),	implemented	in	the	University	of	 California,	 Santa	 Cruz,	 Genome	 Browser	 (71),	 we	 extracted	 the	 vertebrate	homologs	across	100	species	including	primates,	mammals,	birds	and	fish,	while	we	 obtained	 the	 invertebrate	 homologs	with	 FlyBase	 implemented	 InParanoid	algorithm	(72).		
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CREATION OF MUTANT EXPRESSION VECTORS 
As already discussed above we created primers (Table 7), bearing the mutation in 
exam, to be used in site directed mutagenesis kit. 
 
primer 
Forward 
CGAATTTTTCCAGAAAGCAAAGCCCAGTTTGC 
primer 
Reverse 
GCAAACTGGGCTTTGCTTTCTGGAAAAATTCG 
Tab. 7:PHD2 primers designed for the Site Directed Mutagenesis kit. 
 
Amplification by PCR was performed, in a volume of 50 µl, according to the protocol 
given in table 8., using Phusion Hot Start II HF DNA polymerase (Life Technologies) 
following temperature cycles described in table 9.  	 Quantity	(µl)	5X	GC	rich	reaction	buffer		 10	Plasmide	(50ng/µl)	 1	Primers	(100ng/µl)	10µM	(0,3	µM	final)	 1,5	DMSO	 1	DNTPs	50mM		 1	PHUSION	Hot	Start	II	HF	Dna	polymerase	 O,5	(2,5U/µl)	H20	(qsp	50µl)	 33,5	
Tab. 8: Site Directed Mutagenesis amplification reaction mix 
 Temperature	 Time	 Cycle	98°C	 1min	 1	98°C	 10s	 6		55°C		 1min		72°C	(30’’/kb)	 4min	98°C	 10s	 20		65°C		 1min		72°C	(30’’/kb)	 4min	72°C	 10min	 1	
Tab. 9: Thermal profile of the mutagenesis reaction 
 
Once completed, the PCR reaction was cooled in ice for 2 minutes.  
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To digest the plasmid used as a mold (without mutation) we added 1µl of DpnI 
restriction enzyme specific for methylated DNA (Thermo Scientific, 20 U/µl). The 
digestion reaction takes place at 37° C and lasts an hour. The yield of the reaction was 
evaluated with electrophoresis on agarose gel 1% stained with Gel Red (Biotium). 
The obtained constructs were then cloned into ultracompetent BL21 bacterial cells 
(NEB) according to the protocol in table 10 and the isolated clones were amplified in 
5ml miniculture of LB (Luria Bertani) medium containing ampicillin at 0.1%. It was 
then extracted with miniprep plasmid DNA kit (Macherey Nagel) and sequenced to 
verify the goodness of site directed mutagenesis (Figure 12). 
 1	 Add		1µl	mut.	react.	in	50µl	of	BL21	2	 30’	in	ICE	3	 Heat-shock	at	42°C	for	30’’	4	 2’	in	ICE	5	 Add	250µl	of	SOC	at	37°C	(Invitrogen)	6	  60 min incubation at 37°C at 225 rpm	7	 Seed on LB agar with antibiotics	8	 Incubation	at	37°C	overnight	
Tab. 10: BL21 transformation protocol 
 
 
Fig. 12: Sequencing of PHD2 mutant plasmid  
 
 
Once assessed the success of site-specific mutagenesis we amplified the bacterial 
colony containing the mutation first in a 20mL midicolture of LB medium 0.1% 
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ampicillin and then in 500mL maxicoluture of LB medium 0.1% ampicillin 
incubating overnight at 37 ° C in 225 rpm shaking. 
The following day the plasmid DNA was extracted with maxiprep kit (Macherey 
Nagel). 
 
In order to test the HIF transcriptional activity, accumulated after 4-6 hours under 
hypoxic conditions (1% O2) in HEK293T cells, we developed a Dual Luciferase 
Reporter (DLR) Assay (Promega) (44). We used a pGL3 vector that expresses the 
firefly luciferase under the control of the HRE promoter activated by HIF. 
Genetic reporter systems are widely used to study the physiology and gene expression 
in eukaryotic cells and the DLR Assay allows to increase the experimental accuracy 
(73). The term "dual luciferase" in fact refers to the simultaneous expression and 
measurement of two individual reporter enzymes in the same system: the firefly 
luciferase derived from Phatinus pyralis (Fluc) is used as an experimental reporter, 
and Renilla luciferase as internal control which the constitutive expression is given by 
cytomegalovirus promoter (CMV). 
In this assay the activity of both luciferase are measured in a sequential manner from 
the same cell extract. It is based on the substrate specificity: the Fluc activity is 
measured by adding Luciferase Reporter Assay II (LAR II) and, after quenching with 
the addition of Stop & GLO reagent, is detected the activity of Renilla luciferase. The 
Fluc activity is then normalized by the activity of Renilla in order to minimize any 
variable, such as differences in the number of viable cells, the efficiency of 
transfection and lysis, which could undermine the experimental accuracy (Figure 13). 
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Fig. 13: Dual Luciferase Reporter Assay 
 
The functional consequences of the mutation in the activity of PHD2 was then 
assessed by a hypoxia reporter assay detecting the transcriptional activity of 
endogenous HIF accumulated in hypoxic conditions. 
We performed the DLR assay in HEK293T cells, grown in DMEM-Low glucose 
supplemented with 10% FBS, Pen-Strep and L-Gly. We seeded 2x105 cells per well in 
12-well plates 24 hours before transfection. For the transient transfection was used 
Lipofectamine 2000 (Invitrogen). 
The cells were then transfected with 100ng of vector containing Fluc under control of 
HRE, 20ng of Renilla and a range of amounts of PHD2-WT or mutated plasmid. 
The enzymatic activity of Fluc was measured 24 hours after transfection in both 
normoxic or hypoxic conditions. Furthermore we also evaluated the amount of PHD2 
cells production with immunoblot analysis using mouse monoclonal antibodies anti-
HA (Santacruz). 
In order to minimize the noise given by endogenous PHD2, we performed the same 
experiment in REPC cells silenced for PHD2. 
PHD2 is a member of the Fe(II) and 2-OG-dependent oxygenase superfamily in 
which almost all members follow the same overall reaction mechanism: the substrate 
(HIF-α) is hydroxylated in the presence of co-substrates (2-OG, dioxygen) and 
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cofactors (Fe(II) and ascorbic acid). The reaction is accompanied by oxidative 
decarboxylation of 2-OG giving CO2 and succinate (Figure 14)			
 Fig. 14: Hydroxylation reaction of PHD2 enzyme with all cofactors. 
 
To evaluate the ability of mutant PHD2 to hydroxylate HIF2α we tuned an in vitro 
assay. This reaction uses recombinant proteins produced in vitro with wheat germ 
extract to avoid the deriving contamination from endogenous bacteria hydroxylases 
(TNT Coupled Transcription/Translation System Promega). 
The plasmid vectors contain the proline of C-terminal ODD domain of HIF1α (amino 
acids 556-574 or 549-575) and the PHD2 WT or mutated. 
Primarly we used PvuI (Takara) restriction enzyme to linearize plasmid vectors 
containing HIF-ODD, PHD2 WT and mutated PHD2. 
With the TnT Coupled Wheat Germ Extract Systems (Promega) we obtained all 
necessary proteins for the hydroxylation assay.  
This in vitro system allows to have, in a single test tube, high yields of protein 
production to study bypassing all typical problems of standard methods such as long 
working times and transcription/translation problems (Figure 15). 
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Fig. 15: TnT Coupled Wheat Germ Extract Systems (Promega) 
 
After verified the quality of the transcription-translation reaction by immunoblot 
analysis using mouse monoclonal antibodies anti-HA, we continued the hydroxylation 
reaction: in several test tubes we mixed PHD2 WT, or mutated, with HIF1α-ODD 
with all cofactors necessary for the hydroxylation reaction (Fe2 +, ascorbic acid, 2-
oxoglutarate) (Figure 14) (74). 
The hydroxylation reaction was performed at 30°C following a time course at 0, 10, 
30 and 60 minutes. 
Then we compared the hydroxylation ability of the mutant PHD2 to the WT. Thus we 
performed an immunoblot analysis using rabbit monoclonal antibodies specific for 
HIF-OH (Cell Signaling).  
Hydroxylation deficiency of the mutated PHD2 results in the absence of  HIF-OH in 
the blot. 
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FUNCTIONAL STUDY OF TWO EPOR VARIANTS  
For this study we proceeded with the following steps: 
1. Computational study 
2. Construction of mutant plasmids 
3. Transfection 
4. Time course 
 
We performed a study in silico as already written above to understand if the mutations 
could impair the regular functionality of the receptor. 
We created mutated plasmid with site directed mutagenesis kit as explained before. 
 
Primer C338Y Forward gaagtcctctcagagcgctattgggggacgatgc 
Primer C338Y Reverse gcatcgtcccccaatagcgctctgagaggacttc 
 
Primer T341M Forward cactgcctgcatcatcccccagcagcg 
primer T341M Reverse gcatcgtcccccaatagcgctctgagaggacttc 
Tab 11: EPOR primers designed for the Site Directed Mutagenesis kit 
 
 
Fig. 16: Nucleotide sequences of the mutant EPOR plasmids. 
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After the site directed mutagenesis we executed a transient transfection of HEK293T 
cells: 24 hours after seeding 25 cm2 plates, around 80% confluence, we performed the 
transient transfection using jetPEI (PolyPlus) according to the protocol given in table 
12. JetPEI is very convenient because it allows to use the culture medium where cells 
grew even in presence of antibiotics. 
 
1	 Sol	A:	 250uL	NaCl	150nM		+	40	µL	Jet	PEI	(40	µG/reaction)	
2	 Sol	B:	 250uL	NaCl	150nM		+	4	µG	DNA	
3	 		 Mix	Sol	A	+	Sol	B	
4	 		 Vortex	30"	
5	 		 incubation	10'	at	Room	Temperature	
6	 		 add	500	µL	of	mix	A+B	per	plate	
Tab. 12: Transfection protocol with jetPEI chemical agent. 
 
The day after we verified, with Fluorescence Activated Cell Sorting (FACS) 
technique, if the receptor was correctly expressed on the cell membrane (75). The 
FACS technique is a particular type of flow cytometry which allows, after staining 
with fluorescent antibodies, the detection of any epitope. The cells after being labeled 
pass through a capillary of the flow cytometer where they are excited by a laser which 
allows to detect whether the antibody has bound the epitope on the plasma membrane, 
and thus, in our case, if EPOR is expressed or not. 
The experiment is then made by detaching the cells from the plate with PBS-EDTA, 
to avoid to ruin the membrane receptors, and putting 2x105 cells for every transfected 
condition in a well of a 96 well plate. In this way we marked the four conditions 
(empty, wild type, MUT1 and MUT2) with a antibody for the control isotype mouse 
IgG2b Isotype Control (R&D Systems) and, in every different well, with an antibody 
specific to EPOR Human Erythropoietin Mab (R&D Systems). After a series of 
washes with cold  PBS 1X the cells were resuspended and transferred into special 
tubes for the reading with Calibur flow cytometer (Becton Dickinson Bioscience). 
With FACS we could notice that EPOR is expressed in about 50% of the transfected 
cells (Figure 17). 
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Fig. 17: FACS analysis Hek293T cells transfected with EPOR wild type e mutated 
 
With the evidence of the correct expression of EPOR in transfected cells, a second 
transfection was performed according to the same protocol already described. 
48 hours after the transfection we performed a kinetic  of stimulation of the 
transfected cells in the different conditions (empty, WT, MUT1 and MUT2) with 3 
U/ml of hrEPO (Novartis). The stimulation was stopped at time 0, 15, 30 and 45 
minutes. 
Below in table 13, the protocol used: 
1 Morning: Change medium with 5mL DMEM without FBS 
2 Afternoon: deteach cells with PBS-EDTA and put in Falcon 
3 Centrifuge 5' at 1000 RPM 
4 Wash with 4mL PBS 1X and centrifuge 5' at 1000 RPM 
5 Resuspend in 4 mL of DMEM w/o FBS 
 
TIME COURSE 
6 Add EPO (3U/mL) in falcon e mix by inversion 
7 Stop the stimulation with 500uL cold PBS 1X at T0, T15, T30, T45. 
8 Centrifuge at 4°C for 5' at 1000 RPM 
9 Wash with 4mL PBS 1X and centrifuge 5' at 1000 RPM 
10 
Dry pellet: resuspend in 60uL of RIPA buffer (with NaF e Na3VO4) and transfer 
in 1,5 mL eppendorf 
11 Vortex 2-3 min. and tranfer in ICE for 20' 
12 Centrifuge at 4°C for 20' at 12000 RPM 
13 Transfer the supernatant in 1,5 mL eppendorf  
14 PROTEIN TITRATION 
Tab. 13: EPO stimulation protocol of Hek293T cells. 
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Finally, after assessing the concentration of protein extracts with Pierce BCA Protein 
Assay Kit (Thermofisher), we developed Western Blot (WB) investigations analysis 
in order to detect if there are different activation states of the EPOR signaling 
pathway in all different points of the time course in presence or absence of 
stimulation:  
The total protein presence (both activated or not) has been detected with αJAK2 
antibody (Upstate), αSTAT5, αERK, αAKT (Cell Signalling) signal, using β-actin as 
control. We detected the activated proteins using primary antibodies α-phosphoJAK2, 
α-phosphoSTAT5, α-phosphoERK and α-phosphoAKT (Cell Signaling). 
Unfortunately the WB data obtained, with this study approach, were almost null and 
confused although we changed several experiment variables (time of kinetic and EPO 
concentrations). Even by increasing the concentration of primary antibody and 
diluting it no longer in TBST 5% milk but in TBST 5% BSA or in TBST, in order to 
amplify the signal as much as possible, the results were always the same. 
It was necessary to change strategy and to use a cell line that could be a study model 
with characteristics much closer to those in vivo. 
K562 cells are an erythroid leukemia cell line with similar phenotype to the cells 
affected by the disease in vivo (76). This study model is much more truthful than the 
last one with HEK293 cells. 
We grew K562 cell line in RPMI 1640 medium (EuroClone) supplemented with 10% 
FBS (EuroClone), 1% Pen Strep (EuroClone) and 1% L-Glutamine (EuroClone). 
For the experiment we repeated all the steps of those studied for the HEK293T cells 
and also in this case the results were so confused for several reasons: for instance 
transfection with chemical reagents as jetPEI (PolyPlus) had a very low yield. 
However, we completed the experiment of kinetic stimulation but once again the 
results were not significant because very few cells expressed EPOR transfected. 
For the following experiments we adopted electroporation to transfect K562 cells 
(77). Electroporation consists in a sudden electrical discharge operated in a cuvette 
which contains cells and DNA molecules in a liquid suspension. The electrical field 
opens simultaneously different transient pores in the cell membrane at numerous 
points, allowing the DNA molecules to penetrate (Figure 18). It is possible to 
optimize the electroporation parameters for the different types of cell lines by varying 
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the electric field intensity and the duration of the treatment. The area of the 
permeabilized membrane is directly proportional to the electric pulse intensity, while 
longer it lasts in time greater is the disruption of the area. 
 
 
Fig. 18: transient pores formation on the cellular membrane after electroporation. 
 
We tested the transfection efficiency with a plasmid encoding Green Fluorescent 
Protein (GFP), using different amounts of cells in the cuvette (1, 3 and 6 million 
cells). Electroporation was performed with an electroporator Nucleofector™ (Lonza) 
according to the protocol given by the company. In each cuvette we transfected the 
defined quantity of cells in 100 µL of Buffer A. 
After 24 and 48 hours, we evaluated the amount of GFP expressed with a 
fluorescence microscope (Leica). We evidenced that the optimal transfection yield is 
with 2 µg of DNA per million cells in a total of 6 million cells (Figure 19). 
 
 
Fig. 19: GFP in A – 1x106, B – 3x106, C – 6x106 cells 48h after trasfection. 
 
Determined the amount of cells to transfect we proceeded with the electroporation of 
plasmids encoding EPOR WT and mutated. Once transfected we seeded 3 million 
cells, for every condition, in 25 cm2 flasks in 5 ml of RPMI 1640 1% FBS. 
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We then analyzed the transfection yield of EPOR plasmids: 
48h after the electroporation we extracted the RNA according to the protocol in table 
14. with High pure RNA isolation kit (Roche). 
 
1 Resuspend cells in 200 µl of PBS 
2 Add 400 µl di Lysis/Binding Buffer and vortex for 15” 
3 Transfer the sample in a High Pure Filter Tube 
4 Centrifuge 15” at 8000 x g 
5 Discard the flowthrough 
6 Add a sol. of 90 µl Dnase I Incubation Buffer + 10 µl Dnase I and incubate 15’ 
at room temperature. 
7 Add  500 µl Wash Buffer I and centrifuge 15” at 8000 x g.  
Discard the flowthrough (Repeat twice) 
9 Add  500 µl Wash Buffer I and centrifuge 15” at 13000 x g.  
Discard the flowthrough 
10 Elute with 50-100 µl  of Elution Buffer e centrifuge 1’ at 8000 x g. 
11 Store at -80° C 
Tab. 14: RNA extraction protocol with High pure RNA isolation kit (Roche). 
 
The RNA was then quantified with NanoDrop and later we performed a 
retrotranscription with a RT-PCR reaction. The mix and the thermal profile of the 
reaction are shown in table 15 and table 16 respectively. 
 
iScript RT Supermix BioRad 4 µl 
RNA 1 µg 
Nuclease-free water variable 
Totale Vol. 20 µl 
Tab. 15: RT-PCR reaction mix 
 
 Temperature °C Time min. 
Priming 25 5 
Reverse Transcription 46 20 
RT inactivation 95 1 
Tab. 16: RT-PCR thermal profile 
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At this point, obtained the cDNA, we executed a qPCR analysis. A relative 
quantification of mRNA of transfected EPOR had been carried out comparing with 
non-transfected cells. We used Actin as house keeping gene. The qPCR was 
performed with StepONE device (BioRad). Reaction mix and the thermal profile are 
shown in table 17 and 18 respectively. 
 
SYBR Green Super Mix BioRad 10 µl 
Primer Forward 2 µl 
Primer Reverse 2 µl 
cDNA 2 µl 
H2O 4 µl 
Total Vol. 20 µl 
Tab. 17: qPCR reaction mix. 
 
T (°C) Time Cycles 
95 3’ 1 
95 10-15”  35-40 
 T. annnealing and Extention 
30-
60” 
Melt Curve 
55 – 95 °C 
 Tab. 18: qPCR thermal profile. 
 
We made a relative quantification relating EPO WT and mutated threshold cycles, to 
those of Actin. After 48h the mRNA of different transfected EPOR conditions is 
expressed about 1800 times more than the sample not transfected. Figure 20 shows 
how the logarithmic phase of transfected samples amplification occurs at much lower 
cycles when compared to the sample not transfected. 
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Fig. 20: Amplification curves of the qPCR reaction. Samples transfected WT and mutated (MUT1 and 
MUT2) display a logarithmic phase of EPOR amplification at much lower threshold cycles when 
compared to amplification cycles of non-transfected (NT) cells. 
 
The week before the experiment we cultured cells  in RPMI 1640 medium with only 
1% FBS in order to synchronize them to be stimulated with EPO (Binocrit - Novartis) 
limiting as much as possible any disturbance derived from FBS. 
Cells were then transfected with electroporation technique as already described, and 
48h after transfection, we performed the stimulation kinetic according to the protocol 
in table 19. 
 
STIMULATION KINETIC 
1 Transfer the cells Falcon 
2 Add EPO (3U/mL) in Falcon and mix by inversion 
3 
  
Stop the stimulation with 500µL of cold PBS 1X  
at T0, T5, T15, T30, T45. 
4 Centrifuge 5' at 1000 RPM 
5 Wash with 4mL PBS 1X and centrifuge 5' at 4°C at 1000 RPM 
6 
Dry pellet: resuspend in 60µL RIPA buffer (with NaF e Na3VO4) 
and transfer in 1,5 mL Eppendorf  
7 Vortex 2-3 min. and transfer on ICE for 20' 
8 Centrifuge at 4°C for 20' at 12000 RPM 
9 Transfer surnatant in a 1,5 mL Eppendorf 
10 PROTEIN TITRATION 
Tab. 19: EPO stimulation kinetic of K562 cells.  
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After the quantification of the protein extracts we performed WB analysis of various 
components of the EPOR signaling pathway such as JAK2, STAT5, ERK and AKT 
using the β-actin as house keeping. The SDS-PAGE was carried out in MES running 
buffer (Invitrogen) loading 35 micrograms of protein in NuPAGE Bis-Tris Mini gel 
(Novex). 
Primary antibodies are αP-STAT5 a/b (Y694/Y699 R&D Systems), αSTAT5 (C-17 
Santa Cruz), αP-Akt (S473 R&D Systems), αAkt 1/2/3 (H-136 Santa Cruz) , αP-ERK 
(E-4 Santa Cruz), αERK1 (K-23 Santa Cruz), αP-Jak2 (Y1007-1008 C80C3 Cell 
Signaling), αJak2 (D2E12 XP Cell Signaling), while for secondary antibodies we 
used IRDye 680RD Donkey αMouse (LI-COR) and IRDye 800CW Donkey αRabbit 
(LI-COR). 
After incubation with secondary antibodies we developed the blot with Odyssey 
method (Li-Cor) which involves the use of a scanner Odyssey Infrared Imaging 
System (Li-Cor) whose secondary antibodies are IR sensitive. 
We also analyzed the WB results with the software Image Studio developed by Li-
Cor, to obtain the quantification of the signal. Furthermore it permitted us to 
implement the background reduction and adjust the brightness/contrast of the WB 
images. 
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RESULTS 
 
Within the 106 patients (89 males, 17 females) JAK2-WT (Table 20 ) evaluated, in 97 
we did not recognize any mutations in the indices genes nor we can identify any other 
case of erythrocytosis in the patient kindred: these patients were considered as 
sporadic IE.  
 Not mutated mutated 
N° of patients (106 total) 97 9 
Male (%) 81 (83,5) 8 (88,9) 
Mean age (y) 52,8±16,4 24±20 
Mean HB g/L 179,8 185,6 
Mean HCT (%) 53,16 56,4 
Mean WBC (x109/L) 7,5±2,7 8,1±3,7 
Mean plts (x109/L) 222±67 236±74 
Median EPOs (UI/L) (range) 11 (4-38) 52 (5-1280) 
Patients with EPOs lower than normal 
limits (%) 24/73 (32,8%) 3 (33%) 
Patients with EPO higher than normal (%) 49/73 (66.2%) 6 (66%) 
Tab. 20: Main clinical and laboratory data at diagnosis of our patients. 
 
Nine patients had one of the mutations of EPOR or of OSP genes: 2 in EPOR gene, 2 
in the VHL (2 other patients had classical VHL R200W), 2 in HIF2α, and a 1 in 
PHD2 (Table 21). 
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 N° of patients New mutations  
Yet known 
mutations 
VHL 4 2 - (R82C - G144R) 2 - (R200W) 
PHD2 1 1 - (G349S) / 
HIF2α 2 2 - ( R550W - R602Q) / 
EPOR 2 2 - (C338Y - T341M) / 
Tab. 21: Mutations found within 106 patents with not-MPN erythrocytosis  
 
The two missense mutations in the VHL gene map in respectively exon 1 and exon 2, 
in a region that encodes the interaction domain with HIF2α. The variation c.244C>T -
p.Arg82Cys mutation induce a change between a positively charged amino acid and a 
polar one. The mutation c.430G>A - p.Gly144Arg causes the substitution of a 
positively charged amino acid with a polar amino acid (78)  (Figure 21). 
 
 
Fig. 21: Mutations detected in functional domain of VHL. 
 
 
 
	 49	
We found two missense mutations in HIF2α gene (c.1648C>T – p.Arg550Trp and 
c.1805G>A – p.Arg602Gln) both mapping in exon 12. This exon encodes the domain 
hydroxylated by PHD2. We have not at present evaluated the effect of these 
mutations on the protein function. 
 
 
Fig. 22: 2 missense mutations detected in exon 12 of HIF2α gene. 
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The mutation c.1045G>A – p.Gly349Ser in PHD2 gene is located in exon 3 that 
encodes part of the dioxygen domain responsible for the binding of with O2 molecule. 
This binding allows the hydroxylation of HIF2α and therefore its degradation (Figure 
23). 
 
 
Fig. 23: PHD2 gene and the missense mutation found in exon 3. 
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In EPOR gene, we detected 2 missense mutations both in exon 8 that encodes for a 
negative regulatory domain. The first mutation (c.1013G> A – p.Cys338Tyr) changes 
from a polar to an aromatic amino acid, and the second one (c.1022C>T – 
p.Thr341Met) leads to a non-polar instead a polar amino acid (Figure 24).  
 
Fig. 24…: Functional domains of EPOR and the mutations found during the genetic study. 
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FUNCTIONAL STUDY OF THE NOVEL PHD2 MUTATION 
The data emerged from the in silico study showed that the nucleotide variation 
c.1045G>A in PHD2 is not particularly compromising for the protein if compared to 
other more severe mutations (Figure 25).  
	
 
Fig. 26:  Comparison with the new G349S mutation, found in our patients, with Q157H, P200Q and 
R371H non-severe mutations and D254H e H374R defined as severe. 
 
However, considering that the mutant residue maps in a highly conserved domain 
present in many animal kingdoms, we decided proceed to the functional studies 
anyway ( Figure 26). 
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Fig. 26: The alignment of the various isoforms of PHD2 in the various animal kingdoms shows that the 
mutation G349S maps in a widely conserved domain. 
 
 
The data obtained from the DLR in cellulo assays show that the mutation PHD2 
G349S does not display relevant differences compared to the wild type protein. 
In fact, as can be seen in figure 27, the luciferase activity in cells transfected with 
PHD2 G349S is comparable to that of PHD2 WT cells: the mutated PHD2 enzyme 
did not developed a big luciferase activity due to lack of hydroxylation of HIF, as  
seen with the control (a patient carrying D254H mutation). 
We found the same results for the experiments conducted in cell line REPC-Sh-PHD2 
(Figure 28). 
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Fig. 27: Dual Luciferase Reporter Assay in Hek293T cells transfected with several amount of mutant 
(R371H as severe and D254H as not-severe) or PHD2 WT vector. Under the graph there is a blot 
showing the amount of enzyme PHD2 produced by the transfected cells. 
 
 
Fig. 28: Dual Luciferase Reporter Assay in REPC cell line silenced for PHD2 and transfcted with 
several amount of mutant or PHD2 WT vectors. 
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The in vitro hydroxylation test did not show differences of PHD2 enzymatic activity 
between the mutated protein and the wild type one: the WB analysis reveal that the 
amount of hydroxylated HIF-ODD is almost similar with PHD2 WT and with PHD2 
G349S. In contrast, with the negative control (PHD2 P317R) hydroxylated HIF-ODD 
is totally absent (Figure 29). 
 
 
Fig. 29: Western Blot analysis of the hydroxylation test in which an antibody specific for HIF-ODD 
hydroxylated had been used. 
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FUNCTIONAL STUDY OF THE EPOR MUTATIONS 
The study in silico indicates that  EPOR c.1013G>A and c.1022C>T mutations are 
not severe: however, the missense mutations with aminoacid changes can compromise 
the protein characteristics: Especially c.1013G>A mutation may affect the splicing 
mechanism (Figure 30) and then the correct maturation of mRNA.  
 
 
Fig. 30: Computational study conducted for the EPOR gene mutations. In both mutations there is an 
amino acid change with possible impairments of the characteristics of the protein. For the mutation 
c.1013G>A is also provided a variation of the splicing site.  
 
WB analysis (Figure 31) display that the EPOR signaling cascade is more active in 
mutated cells than the WT when stimulated with EPO. The signal transducer STAT5 
is more active in C338Y cells than the T341M at 5 to 15 minutes after the stimulation 
with the cytokine. 
The mitogen-activated protein kinase ERK appeared more active in the mutated 
conditions compared to the WT at the point T0 and the same activating condition is in 
T5, and also in the other points of the time course suggesting that the receptor is 
constitutively active in absence of EPO stimulation. Mild activation in mutant 
conditions, had also been detected in T15 and T30. These results are also confirmed 
with the WB signal quantification made with the sofware Image Studio powered by 
Li-Cor (Figure 32). 
The phosphorylated transcription factor Akt is very weak just in step T5 (doubtful 
interpretation). No activation signal was detected in kinase JAK2. 
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Fig. 31: The EPOR signaling cascade resulted more active in mutated cells than in the WT when 
stimulated with EPO. 5’ and 15’ after stimulation, transfected cells with C338Y mutation showed 
higher phosphorylation of STAT5 compared to T341M mutation.  
We observed also a similar phosphorylation pattern of ERK occurring earlier than STAT5 (at 0’ and 
5’), while no activity signals were detected in JAK2 and AKT cascades. 
 
 
Fig. 32: Quantifications of  WB signal confirm the major activation of the signal pathway in mutated 
condition (3,4 and 7,8) compared to the not transfected (1 and 5) and the wild type (2 and 6). 
Furthermore P-ERK quantification is more relevant in mutated conditions already in absence of EPO 
suggesting the constitutively activation of EPOR. 										
	 58	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 59	
DISCUSSION 
 
Erythrocytosis is a relatively rare finding in the clinical practice. Most studies on this 
topic are devoted to the patients with PV. These patients are affected by a neoplasms, 
their history is characterized by frequent thrombotic events and they may evolve in 
myelofibrosis and acute leukemia. Therefore, most Hematologists have been attracted 
by this disease (18). 
In contrast, CE are extremely rare diseases (56). They can be either primary or 
secondary disorder, depending by the gene involved: the mutations in OSP genes are 
considered secondary disorders, because they induce an increased EPO production 
that stimulates the erythroid proliferation (29). In contrast, mutations in EPOR gene 
directly interest the erythroid progenitors and therefore are classified as primitive 
disorders (28).  
In our Center, we meet many patients with erythrocytosis. When we exclude in 
sporadic cases a PV not finding JAK2 V617F or JAK2 ex 12 mutations, we perform 
the germinal DNA investigation on the basis of EPOs level: in the presence of high 
EPOs, we explore the genes of the OSP and if EPOs is low we study the EPOR gene. 
We found that it is possible to recognize rare mutations not only in familial cases but 
also in sporadic patients. In the past, we published the data of a child with very high 
HCT carrying a never previously published VHL mutation (78). The mother and one 
of the sisters had the same mutation but they do not have the phenotype 
All the mutations we found are heterozygous and our previous experience in a VHL 
mutated patient induced us to evaluate EPOR and OSP genes in a large cohort of 
otherwise considered IE.  
Within 106 cases, we found 9 gene mutations [4 mutations of VHL (2 classical 
Chuvash mutation, 1 yet published by us and 1 never described), 1 new mutation in 
PHD2, 2 mutations in HIF never described and 2 novel mutations of EPOR] on a 
whole accounting for 8,5% of all IE followed in our centre. 
The present study deal with one patient carrying a new PHD2 mutation and two 
unrelated patients with 2 different EPOR mutations. None of these 3 patients have 
available relatives to study, and only in one with EPOR mutated gene we were 
informed that his died father had “thick blood”. Therefore, we had no chance to 
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evaluate the kindred of these patients and they result “sporadic” at least from a 
clinical point of view. 
Here, we report functional evaluation of the proteins produced by mutated PHD2 and  
EPOR gene. These three mutations have never been previously described. 
The PHD2 mutation we found is a missense mutation (c.1045G>A - p.Gly349Ser) 
(79, 80). It does not induce a clear loss-of-function, while PHD2 D254H and H374R 
mutations showed a functional activity of the enzyme. Other studies described that 
mutations Q157H, P200Q and R371H are not active (42, 81). Therefore, these 
mutations as well as our one are weaker than the first described and more sensitive 
methods should be used to evaluated their function.  
We can also suppose that, in the case of weak mutations, other genes may be involved 
in the development of erythrocytosis. Unfortunately, the absence of an evaluable 
kindred did not facilitate the identification of the targeted genes that should be 
investigated after surveys by Next Generation Sequencing (NGS). 
In EPOR gene, we found two different mutations: c.1013G> A - p.Cys338Tyr and c. 
1022C>T - p.Thr341Met (82). The two new mutations of the EPOR gene here 
reported represent about 8% of already published EPOR mutations. They are located 
in exon 8 as all the 26 previous described functional mutations and impair the C-
terminal negative regulatory domain resulting in a gain-of-function in the EPOR 
signaling cascades both in C338Y and in T341M mutation.  
These novel mutations, causing hyperactivity, increase proliferation and 
differentiation (effect of ERK pathway), and decrease of apoptosis of erythroid 
progenitor (effect of STAT5 pathway), sustain the erythrocytotic phenotype of our 
patients. The future evaluation of the effect on NFKB and on GATA1 should confirm 
the anti-apoptotic effect of the mutations. 
We underline that these mutations are both missense and no previous descriptions are 
available in the literature about functional effect of missense mutations on the signal 
cascade of EPOR signaling.  
 
This study give a contribute to the knowledge of CE. Significant advances have been 
made during the past decade in this filed (83) and the incoming use of NGS is 
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expected to further expand the number of genes involved in erythrocytosis, causing a 
reduction of idiopathic forms (84). 
Our study also shows that erythrocytotic sporadic patients may have a mutation in the 
presently known genes involved in erythrocytosis, and we suggest to explore these 
genes in all patients with erythrocytosis when a clear ethiology is not recognized, 
even if this is an evident economical aspect that must be considered. 																																					
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